Vol. 44 (5): 859-861, September – October, 2018
doi: 10.1590/S1677-5538.IBJU.2018.05.02
DIFFERENCE OF OPINION
Brunno Raphael Iamashita Voris 1, Carolina Del Negro Visintin 2, Leonardo O. Reis 1, 3, 4
1 Departamento de Urologia, Universidade Estadual de Campinas, Unicamp, Campinas, SP, Brasil; 2 Departamento de Ginecologia, Pontifícia Universidade Católica de Campinas, PUC -Campinas, SP, Brasil; 3 UroScience, Campinas, SP, Brasil; 4 Departamento de Urologia, Pontifícia Universidade Católica de Campinas, PUC – Campinas, SP, Brasil
Keywords: Human papillomavirus 31; Penile Neoplasms; Vaccination, Male
Penile cancer is a rare tumor in developed countries; since its diagnosis is made usually in a late stage, it presents high morbidity and mortality. It is more prevalent in developing countries in Asia, Africa and South America, particularly in non-circumcised males (1). More common histology type is penile squamous cell carcinoma – PSCC (95%) related to the infection by the Human Papillomavirus (HPV) (2). HPV-DNA is found in more than 20% of patients with penile tumor and in 90% of anal cancers (3). The number of new patients with PSCC is increasing worldwide, including developed European countries (Denmark, Netherlands, England), and has been worried many health care professionals around the World (4).
